• Our Science

    Programs developing molecules to amplify immune recognition of cancers

  • Clinical Trials

    Targeting various cancers either in monotherapy or in combination

  • Working at iTeos

    Recruiting top talent for both our US and Belgium sites

Pipeline

iTeos focuses upon selected key mechanisms by which cancer cells suppress the immune system.

The identification of these mechanisms is based on gene expression profiles of immune cell subsets as they recognize tumor cell targets, protein expression in human tumors and demonstration of proof of concept by blocking these mechanisms in a variety of laboratory models.

Learn more about our pipeline
Program Trial Design Indications Preclinical Phase 1 Phase 1b/2a Key upcoming milestones
EOS-850
Monotherapy Solid tumors
Initial expansion results 1H 2021
+ pembrolizumab PD-1-Resistant Melanoma
Initiation 3Q 2020
+ pembrolizumab Castrate-R Prostate Cancer
Initiation 3Q 2020
+ Pac-Carbo TNBC
Initiation 3Q 2020
EOS-448
Dose Finding, PK/PD Solid tumors
Presentation of initial results 1H 2021
Mono / + Combo Multiple Myeloma
Initiation mid-2021
+ PD-(L)1 NSCLC
Initiation mid-2021
+ EOS-850 +/- Chemo Solid Tumors
Initiation mid-2021
Adenosine Pathway Inhibitor
Oncology
Candidate selection 1Q 2021

Our latest news

  • iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020
    Clinical Trials Corporate Research TIGIT

    iTeos Therapeutics Presents Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020

    – EOS-448 is being investigated in a Phase 1/2a clinical trial in advanced solid tumors and the dose escalation portion of the trial was initiated in February 2020 – – EOS-448 has shown potent antitumor activity and a favourable tolerability profile in preclinical studies –   Cambridge, MA and Gosselies, Belgium – June 22, 2020. iTeos Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, is presenting preclinical data for its investigational FcγR-engaging anti-TIGIT antibody, EOS-448, in a virtual poster presentation at the American Association of Cancer Research II (AACR II) Virtual Annual Meeting 2020, taking place June 22-24th. EOS-448 has demonstrated strong functional activity and a clean safety profile in its preclinical studies. iTeos enrolled the first patient in the dose escalation portion of its Phase 1/2a study with EOS-448 in February, 2020. “We are excited to have started the Phase 1 portion of our first-in-human studies with our  FcγR-engaging anti-TIGIT antibody, EOS-448, which has demonstrated strong antitumor activity both as single agent and in combination as well as a clean tolerability profile in preclinical studies,” said Michel Detheux, Chief Executive Officer of iTeos Therapeutics. “We believe EOS-448 has significant potential to be beneficial to cancer patients in the clinic, on the basis of its potent activity in restoring antitumor immunity in preclinical studies, supported by its multiple mechanisms of action, as well as by the latest clinical data reported for compounds of the same class.” Summary of the Data to be Presented EOS-448, a novel FcγR-engaging anti-TIGIT antibody, is shown to be highly potent and demonstrates strong anti-tumor activity and a clean safety profile in the preclinical setting. In addition to its ability to reverse immunosuppression of NK and effector T cells, EOS-448 is an IgG1 antibody, and has been able to induce potent and preferential cytotoxicity directed against Tregs as compared to CD4 and CD8 effector cells. Characterization of cell populations show that tumor-infiltrating Tregs exhibit differentially high levels of TIGIT, making these cells preferentially susceptible to ADCC. Furthermore, among tumor-infiltrating lymphocytes, or TILs, CD4 and CD8 T cells  expressing high levels of TIGIT typically display an exhausted profile. In preclinical tumor models of pre-established tumors, EOS-448 demonstrated strong tumor growth delay activity as a single agent and when combined with anti-PD-1 antibody, further increased the antitumor activity and resulted in complete responses in seven out of eight mice. The observed antitumor activity correlated with an increase of IFNγ-secreting CD4 and CD8 T cells and preferential Treg depletion within the tumor microenvironment. When the same anti-TIGIT clone was built on an antibody isotype with low FcγR binding capabilities and tested in the same model, or when our anti-TIGIT EOS-448 was dosed in FcγR knockout mice, antitumor activity was lost demonstrating the key role of FcγR engagement for the therapeutic activity of anti-TIGIT therapies. When tested in NHP, EOS-448 demonstrated a dose-proportional increase in exposure with a classical human IgG1 profile. The increase in exposure correlated with increased target engagement. We observed full occupancy of the TIGIT receptor which was maintained for at least 1 week at the highest tested dose. EOS-448 was shown to have a favorable tolerability profile  in these preclinical toxicology studies, and the NOAEL was the highest tested dose of 10mg/kg. The abstract and video presentation details are as follows: Title: Preparation of a clinical trial with a-TIGIT antagonist antibody EOS-448, which demonstrates potent preclinical activity and safe toxicology profile Session:  Immune Checkpoints 4 Abstract #: 3720 Poster #: 3161 Authors: Thi Lien-Anh Nguyen, et al. The abstract was posted online at 12:01 a.m. EDT on Friday, May 15 on the AACR conference website. The e-poster website will be launched today, June 22, the first day of the AACR Virtual Annual Meeting II. All e-posters will be made available for browsing on this date. EOS-448 Clinical Development (ClinicalTrials.gov Trial Identifier: NCT04335253) This Phase 1/2a study of EOS-448 is an open-label, dose-escalation study to assess the safety, pharmacokinetic, pharmacodynamic and preliminary clinical activity of EOS-448 in participants with advanced cancers. Participants’ tumors will be sampled before treatment and during treatment, to identify and confirm biomarkers to be used in further clinical development. Following dose escalation and determination of the recommended Phase 2 dose, the study design allows for the seamless expansion of patient cohorts to evaluate the anti-tumor activity of EOS-448 in specific tumor types. The trial will be conducted at multiple clinical sites in Europe and is expected to enroll approximately 30 patients with advanced cancer represented in the dose escalation portion. About iTeos Therapeutics iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is being investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors and encouraging preliminary single-agent activity were observed in the dose escalation portion of the trial. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. EOS-448 was also designed to engage the Fc gamma receptor, or FcγR, to promote antibody-dependent cellular cytotoxicity, or ADCC, activity, including the elimination of tumor-infiltrating regulatory T cells, or Tregs. An open-label Phase 1/2a clinical trial of EOS-448 was recently initiated in adult patients with advanced solid tumors. In April 2020, the Company  closed a $125 million Series B-2 financing from leading biotech investors including RA Capital, Boxer Capital, MPM Capital, Janus Henderson Advisors, RTW Investments, Invus, HBM Partners, Fund+, Vives II, SRIW and SFPI. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.  For further information, please contact:   Michel Detheux, CEO iTeos Therapeutics Inc info@iteostherapeutics.com   Amber Fennell, Paul Kidwell Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe, Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com  

  • iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020
    Research TIGIT

    iTeos Therapeutics to Present Preclinical Data for its Anti-TIGIT antibody, EOS-448, at the AACR II Virtual Annual Meeting 2020

    Cambridge, MA and Gosselies, Belgium – June 15, 2020. iTeos Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced today that it will present preclinical data for its investigational FcγR-engaging anti-TIGIT antibody, EOS-448, in a virtual poster presentation at the upcoming American Association of Cancer Research II (AACR II) Virtual Annual Meeting 2020 taking place June 22-24th. iTeos Therapeutics enrolled the first patient in its Phase 1/2 clinical trial with EOS-448 in solid tumors in February 2020. The abstract and video presentation details are as follows: Title: Preparation of a clinical trial with a-TIGIT antagonist antibody EOS-448, which demonstrates potent preclinical activity and safe toxicology profile Session: Immune Checkpoints 4 Abstract #: 3720 Poster #: 3161 Authors: Thi Lien-Anh Nguyen, et al. The abstract was posted online at 12:01 a.m. EDT on Friday, May 15 on the AACR conference website. The e-poster website will be launched on June 22, the first day of the AACR Virtual Annual Meeting II. All e-posters will be made available for browsing on this date. About iTeos Therapeutics iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors and encouraging preliminary single-agent activity were observed in the dose escalation portion of the trial. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. EOS-448 was also designed to engage the Fc gamma receptor, or FcγR, to promote antibody-dependent cellular cytotoxicity, or ADCC, activity, including the elimination of tumor-infiltrating regulatory T cells, or Tregs. An open-label Phase 1/2a clinical trial of EOS-448 was recently initiated in adult patients with advanced solid tumors. In April 2020, the Company closed a $125 million Series B-2 financing from leading biotech investors including RA Capital, Boxer Capital, MPM Capital, Janus Henderson Advisors, RTW Investments, Invus, HBM Partners, Fund+, Vives II, SRIW and SFPI. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.  For further information, please contact: Michel Detheux, CEO iTeos Therapeutics, Inc. info@iteostherapeutics.com   Amber Fennell, Paul Kidwell Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics Strengthens Leadership Team
    Corporate Financial Research

    iTeos Therapeutics Strengthens Leadership Team

    – Matthew Gall joins as Chief Financial Officer   – Dr Yvonne McGrath joins as Vice President of R&D  – Philippe Brantegem joins as Vice President of Human Resources  Cambridge, MA and Gosselies, Belgium – June 9, 2020 – iTeos Therapeutics Inc., a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced today the appointments of Matthew Gall as Chief Financial Officer, Dr. Yvonne McGrath as Vice President of R&D and Philippe Brantegem as Vice President of Human Resources. “Matthew, Yvonne and Philippe are important additions to the growing iTeos Therapeutics leadership team and their unique skills and breadth and depth of experience will undoubtedly help to progress our pipeline, including our adenosine A2A receptor antagonist (EOS-850) and our anti-TIGIT antibody (EOS-448) programs, and position the company well for accelerated growth in the years to come,” said Michel Detheux, Chief Executive Officer of iTeos Therapeutics. “I am excited to join the iTeos team at this important time in the company’s growth. The talented personnel, highly differentiated immuno-oncology therapeutics and strong investors, position the company well as we pursue new treatments for people living with cancer,” said the new Chief Financial Officer of iTeos Therapeutics, Matthew Gall. Matthew Gall joins iTeos Therapeutics from Sarepta Therapeutics, Inc. where he was the Senior Vice President of Corporate Development and Treasurer. At Sarepta, Matthew led the Company’s recent multibillion partnership deal with Roche, and during his tenure, he oversaw the Company’s financial strategy and helped raise over $2 billion in capital. During his 15-year career in biotech, Matthew also worked at Celgene Corporation and Gilead Sciences in various roles including financial management and business development. Matthew holds an MBA from the University of Chicago Booth School of Business. Dr. Yvonne McGrath joins iTeos Therapeutics from Complix N.V. where she served as the Chief Scientific Officer. Yvonne has worked in the biotech industry for over 20 years, including a position as Head of Development at Immunocore, in addition to R&D management positions at Medigene and Biovex. Yvonne holds a Ph.D. from the University of Wales, College of Medicine, UK. Philippe Brantegem has delivered human resources support to biopharmaceutical companies such as Merck Sharp & Dohme, Besins Healthcare, Sanofi Pasteur MSD and Korn Ferry for over 20 years. Philippe holds master’s degrees in human resource management from the Université Libre de Bruxelles and in public administration from the Solvay Business School. About iTeos Therapeutics iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors and encouraging preliminary single-agent activity were observed in the dose escalation portion of the trial. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. EOS-448 was also designed to engage the Fc gamma receptor, or FcγR, to promote antibody-dependent cellular cytotoxicity, or ADCC, activity, including the elimination of tumor-infiltrating regulatory T cells, or Tregs. An open-label Phase 1/2a clinical trial of EOS-448 was recently initiated in adult patients with advanced solid tumors. In April 2020, the Company closed a $125 million Series B-2 financing from leading biotech investors including RA Capital, Boxer Capital, MPM Capital, Janus Henderson Advisors, RTW Investments, Invus, HBM Partners, Fund+, Vives II, SRIW and SFPI. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium. For more information, please visit www.iteostherapeutics.com.   Michel Detheux, CEO iTeos Therapeutics, Inc. info@iteostherapeutics.com   Amber Fennell, Paul Kidwell Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. +1 212 362 1200 iTeos@sternir.com  

  • iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors
    Corporate Financial

    iTeos Therapeutics Appoints Ann D. Rhoads to Board of Directors

    Cambridge, MA and Gosselies, Belgium – June 1, 2020 – iTeos Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, announced today the appointment of Ann D. Rhoads to its Board of Directors. Ms. Rhoads brings over 25 years of corporate and financial expertise in the life sciences and healthcare industry. "I am delighted to welcome Ann to our Board of Directors at a transformational point in the company’s history. Having recently completed our $125 million Series B-2 financing with a strong investor syndicate, we are now poised to progress the clinical development of our two highly innovative oncology pipeline programs, an adenosine A2A receptor antagonist, EOS-850, and an anti-TIGIT antibody, EOS-448," said David Hallal, Chairman of the iTeos Therapeutics Board. "Ann is a proven leader and brings ideal expertise to our Board. I look forward to working with her and our other Directors to collaborate with the management team as they seek to drive the development of therapies that have the potential to transform the lives of patients suffering with cancer.” “Ann has an impressive track record in executive management in our industry, specifically in the immuno-oncology space; her extensive experience will be instrumental to us as we continue on our growth trajectory. I am thrilled to welcome her to the Board and to draw from her expertise,” added Michel Detheux, PhD, President and Chief Executive Officer of iTeos Therapeutics. Ms. Rhoads most recently served as the Chief Financial Officer at Forty Seven, Inc., a clinical stage immuno-oncology company, from 2018 until its sale to Gilead in 2020. During her tenure at Forty Seven, Inc., it completed an initial public offering and two subsequent public equity financings. From 2010 to early 2017, she was Executive Vice President and Chief Financial Officer at Zogenix, Inc. where she oversaw all areas of financial management, including the company’s initial public offering and subsequent public equity and debt financings. Prior to joining Zogenix in 2010, Ms. Rhoads was Senior Vice President and Chief Financial Officer of the healthcare improvement company Premier, Inc.. Ms. Rhoads started her career as an investment professional with Merrill Lynch and the Sprout Group, the venture capital affiliate of Donaldson, Lufkin & Jenrette (now part of Credit Suisse). Ms. Rhoads holds an M.B.A. from Harvard Business School and a B.S. in Business Administration with a focus on Finance from the University of Arkansas. "iTeos is progressing two innovative immunotherapy candidates through the clinic, both of which are highly differentiated from other programs in clinical development," commented Ann Rhoads. "I look forward to working with the management team and Board of Directors to help iTeos advance its financial and business objectives using the knowledge and experience I have gained during my career." About iTeos Therapeutics iTeos is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors and encouraging preliminary single-agent activity were observed in the dose escalation portion of the trial. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. EOS-448 was also designed to engage the Fc gamma receptor, or FcgR, to promote antibody-dependent cellular cytotoxicity, or ADCC, activity, including the elimination of tumor-infiltrating regulatory T cells, or Tregs. An open-label Phase 1/2a clinical trial of EOS-448 was recently initiated in adult patients with advanced solid tumors. The Company recently closed a $125 million Series B-2 financing from leading biotech investors including RA Capital, Boxer Capital, MPM Capital, Janus Henderson Advisors, RTW Investments, Invus, HBM Partners, Fund+, Vives II, SRIW and SFPI. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium. For more information, please visit www.iteostherapeutics.com. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics Inc info@iteostherapeutics.com   Amber Fennell, Paul Kidwell Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
    A2A Inhibitor Corporate

    iTeos Therapeutics Presents Data from First-in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020

    – Initial data from the dose escalation portion of the Phase 1/2a trial in 21 cancer patients with advanced solid tumors shows EOS-850 was well tolerated with no dose-limiting toxicities observed – – EOS-850 showed preliminary single-agent clinical benefit in seven patients who continue to present with at least stable disease; two partial responses in heavily-pretreated patients are ongoing – – Identification of recommended Phase 2 dose showing strong foundation for planned expansion cohorts to evaluate EOS-850 as a monotherapy and in combination for several solid tumor indications – Gosselies, Belgium and Cambridge, MA – April 27, 2020. iTeos Therapeutics, a privately-held clinical-stage biotechnology company developing novel cancer immunotherapies, announced today that it will present initial data from the Phase 1 portion of the study of its selective and differentiated A2A receptor antagonist, EOS-850, in a poster presentation at the American Association of Cancer Research (AACR) Virtual Annual Meeting 2020. “We are excited by these data from the Phase 1 portion of the study, in which our highly selective A2A antagonist, EOS-850, had a favorable tolerability profile, as well as promising clinical responses, in cancer patients with advanced solid tumors,” said Joanne Jenkins Lager, M.D., Chief Medical Officer of iTeos Therapeutics. “We have established a recommended Phase 2 dose that was well tolerated and demonstrated favorable target coverage. The single-agent activity, demonstrated by two partial responses in heavily pre-treated patients, shows that EOS-850 is an active drug with a good therapeutic index. These data set a strong foundation for moving into the next stage of development in several expansion cohorts, whether as a single agent or in combination with Merck’s KEYTRUDA® or chemotherapy standard of care agents.” The Phase 1 dose escalation portion of the EOS-850 trial enrolled 21 advanced cancer patients with solid tumors. The trial was a 3 + 3 design and patients were enrolled in five dose levels, receiving EOS-850 orally either once a day (QD) or twice a day (BID). Additional patients could be enrolled at previously cleared dose levels to better define safety, pharmacokinetics and pharmacodynamics. The dose levels tested were 20 mg and 40 mg QD, and 40 mg, 80 mg and 160 mg BID. The primary objectives of the Phase 1 portion of the study were to evaluate the safety and tolerability of EOS-850 and to determine a recommended Phase 2 dose. Secondary study objectives include pharmacokinetic and pharmacodynamic assessment of EOS-850 monotherapy and monotherapy efficacy activity of EOS-850. Summary of the Data Presented All QD and BID dose levels were well-tolerated with no grade 3 or 4 drug-related adverse events. No dose limiting toxicities were observed. Assessment of the pharmacodynamic effects of EOS-850 in assays assessing phosphorylation of CREB and cytokine production, performed by taking blood samples from patients at various time points following administration, demonstrated sustained inhibition of the A2A receptor. Pharmacokinetic analysis demonstrated good dose-proportionality through 80mg BID, the recommended Phase 2 dose. EOS-850 demonstrated preliminary evidence of single-agent activity in seven patients, each of whom had at least stable disease. Ongoing partial responses were seen in a patient with heavily pre-treated checkpoint inhibitor-refractory melanoma and in a patient with metastatic hormone- and chemotherapy-resistant prostate cancer. The abstract and video presentation details are as follows:  Title: First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers (CT152)  Session: Phase I Clinical Trials  Abstract #: 10228  Authors: Laurence Buisseret, et al. The video presentation and full abstract will be available on the AACR conference website as of 9:00 AM ET on Monday, April 27th. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA. EOS-850 Further Clinical Development Plans The primary and secondary endpoints of the dose escalation portion of the Phase 1/2a trial have been met at the recommended Phase 2 dose of 80mg BID. Based on these results, as well as the partial responses observed in two cancer patients with advanced disease, the Company is moving into the expansion cohorts of the study. These cohorts will test EOS-850 as a single agent and in combination with KEYTRUDA® (pembrolizumab) and in combination with chemotherapy. Indications for testing include checkpoint-resistant melanoma, metastatic hormone-resistant prostate cancer, triple-negative breast cancer, endometrial cancer and non-small cell lung cancer. The combination studies will include a safety evaluation of the combinations and then enroll patients in two-stage tumor-specific expansions. Preliminary results of these expansions are expected in the first half of 2021. About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of people living with cancer by designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs). The Company’s lead program, EOS-850, is a potentially best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2a trial. Its second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), entered the clinic in February 2020. The Company recently closed a $125 million Series B-2 financing from leading biotech investors including RA Capital, Boxer Capital, MPM Capital, Janus Henderson Advisors, RTW Investments, Invus, HBM Partners, Fund+, Vives II, SRIW and SFPI . iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium. For more information, please visit www.iteostherapeutics.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics SA info@iteostherapeutics.com   Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com  

  • iTeos Therapeutics to Present Data from First- in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020
    A2A Inhibitor Corporate Research

    iTeos Therapeutics to Present Data from First- in-Human Study of A2A Receptor Antagonist at AACR Virtual Annual Meeting 2020

    Gosselies, Belgium and Cambridge, MA – April 20, 2020. iTeos Therapeutics, a privately-held biotechnology company developing novel cancer immunotherapies, announces today that it will present initial data on the first-in-human study of its highly innovative and differentiated A2A receptor antagonist, EOS-850 in a virtual poster presentation at the upcoming American Association of Cancer Research (AACR) Virtual Annual Meeting 2020, taking place April 27-28th.     The abstract and video presentation details are as follows: Title: First in human study with EOS100850, a novel potent A2A antagonist, shows excellent tolerance and clinical benefit in immune resistant advanced cancers (CT152) Session: Phase I Clinical Trials Abstract #: 10228 Authors: Laurence Buisseret, et al. The video presentation and full abstract will be available on the AACR conference website from 9:00 AM ET on Monday, April 27th. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics SA info@iteostherapeutics.com Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics Closes $125 Million Series B2 Financing
    A2A Inhibitor Clinical Trials Corporate Financial Research TIGIT

    iTeos Therapeutics Closes $125 Million Series B2 Financing

     - Proceeds support advancing clinical development of next-generation cancer immunotherapies targeting A2A adenosine receptor and anti-TIGIT immune checkpoint - - Oversubscribed round co-led by new investors RA Capital Management and Boxer Capital - - New investors Janus Henderson Investors, RTW Investments and Invus also participated along with previous Series B investors including MPM Capital and HBM Partners - Cambridge, MA and Gosselies, Belgium – April 1, 2020 – iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing innovative cancer immunotherapies, announced today the closing of an oversubscribed Series B2 financing, which raised a total of $125 million. The Series B2 financing round was co-led by RA Capital Management and Boxer Capital, and included new investors Janus Henderson Investors, RTW Investments and Invus along with existing investors MPM Capital, HBM Partners, 6 Dimensions Capital, Curative Ventures, Fund+, VIVES Louvain Technology Fund, SRIW, and SFPI. Proceeds from the financing will support the Company's continued growth and advance the clinical development of its two lead product candidates, EOS-850, a best-in-class adenosine A2A receptor antagonist and EOS-448, an ADCC-enabled anti-TIGIT antibody. EOS-850 is currently being evaluated in a Phase 1/2 clinical trial both as a single agent and in combination in several solid tumor indications. The Company plans to initiate dosing for the combination cohorts for this trial in the second quarter of 2020. The Company also recently initiated the Phase 1 portion of a Phase 1/2 clinical study of EOS-448, currently being evaluated in patients with solid tumors and hematological malignancies. Proceeds from this financing will also support the advancement of additional first-in-class preclinical programs targeting the adenosine pathway and Tregs. "We are very pleased to have the strong support of this leading class of investors who share our excitement for the highly innovative oncology therapies we have developed at iTeos,” said Michel Detheux, PhD, President and Chief Executive Officer at iTeos. “We look forward to accelerating and expanding our clinical development efforts to identify the most promising indications and combinations for people suffering with cancer. This financing maximizes our ability to execute our development plans alone or in partnership.” "iTeos’ pipeline of best-in-class agents has the potential to usher in a new wave of immuno-oncology therapeutics and the Company is well-positioned to make a significant, positive impact in the treatment of patients with a wide variety of cancer types,” commented Derek DiRocco, Principal, RA Capital Management. “We are thrilled to collaborate with this experienced group of high-quality investors and partner with the iTeos management team as they continue to innovate and progress these exciting programs through clinical development.” “The iTeos team has done a remarkable job developing a pipeline of differentiated, potentially best-in-class cancer therapies,” said Aaron Davis, Co-Founder and Chief Executive Officer, Boxer Capital of the Tavistock Group.  “We are pleased to be joining them as they continue to execute and implement their vision for transforming the cancer treatment landscape.” Derek DiRocco and Aaron Davis will join the iTeos Board as Non-Executive Directors. About iTeos Therapeutics iTeos Therapeutics is a privately-held, clinical-stage biopharmaceutical company dedicated to transforming the lives of people living with cancer by designing and developing next generation immunotherapies targeting two key resistance pathways to checkpoint therapy: the adenosine pathway and regulatory T cells (Tregs). The Company’s lead program, EOS-850, is a best-in-class adenosine A2A receptor antagonist currently in a Phase 1/2 study. Its second program, a fully human ADCC-enabling anti-TIGIT antibody (EOS-448), entered the clinic in February 2020. iTeos Therapeutics is headquartered in Cambridge, MA with a world-class research center in Gosselies, Belgium. For more information, please visit www.iteostherapeutics.com. About RA Capital Management RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare and life science companies that are developing drugs, medical devices, and diagnostics. The flexibility of its strategy allows RA Capital to provide seed funding to startups and to lead private, IPO, and follow-on financings for its portfolio companies, both facilitating the crossover process and allowing management teams to drive value creation with fewer capital concerns from inception through commercialization. For more information, please visit https://www.racap.com. About Boxer Capital, LLC Boxer Capital, LLC is a private biotechnology investment fund based in San Diego, California that invents and invests in drug development across multiple therapeutic indications.  Founded by the life sciences team at Tavistock Group in 2005, Boxer Capital maintains a concentrated portfolio of public and private companies.  For more information, please visit www.boxercap.com.   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics SA info@iteostherapeutics.com   Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com

  • iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers
    Clinical Trials Research TIGIT

    iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

    – First patient enrolled in dose escalation portion of Phase 1/2 study of EOS-448, an antagonist anti-TIGIT antibody that enables antibody dependent cellular cytotoxicity (ADCC) – – ADCC-enabled TIGIT programs are progressing into pivotal trials – – Initial clinical data expected in 1H 2021 – Cambridge, MA and Gosselies, Belgium – February 27, 2020 – iTeos Therapeutics Inc., a privately-held clinical-stage biotechnology company developing innovative cancer immunotherapies, announced today that it has enrolled the first patient in its Phase 1/2 study with EOS884448 (EOS-448), the company’s investigational ADCC-enabled antagonist anti-TIGIT antibody drug candidate. Michel Detheux, PhD, President and Chief Executive Officer of iTeos, commented: “EOS-448 is an ADCC-enabled antagonist anti-TIGIT antibody that has been designed to maximize the therapeutic benefit of blocking TIGIT checkpoint inhibitors while engaging Fcγ receptors. The importance of TIGIT as a target for next-generation immunotherapy is becoming increasingly apparent in our field and, alongside our best-in-class adenosine A2A receptor antagonist EOS-850, iTeos now has two highly innovative immunotherapy programs in clinical development for patients suffering with advanced cancers.” Joanne Lager, M.D., Chief Medical Officer of iTeos, added, “ADCC-enabled antagonist anti-TIGIT programs are emerging as promising new immuno-oncology therapies. In preclinical studies, EOS-448 promotes anti-tumor immunity both alone and in combination with other oncology therapies. We believe it is well-positioned to provide important new therapeutic options for cancer patients. We look forward to evaluating EOS-448 in our now initiated Phase 1/2 trial and to reporting initial safety and efficacy results in the first half of 2021.” About the EOS-448 Phase 1/2 Trial This Phase 1/2 study of EOS-448 is an open-label, dose-escalation study to assess the safety, pharmacokinetic, pharmacodynamic and preliminary clinical activity of EOS-448 in participants with advanced cancers. Participants’ tumors will be sampled before treatment and during treatment, to identify and confirm biomarkers to be used in further clinical development. Following dose escalation and determination of the recommended Phase 2 dose, the study design allows for the seamless expansion of patient cohorts to evaluate the anti-tumor activity of EOS-448 in specific tumor types. The trial will be conducted at multiple clinical sites in Europe and is expected to enroll approximately 30 patients with advanced cancer in the dose escalation portion. About TIGIT and EOS-448 TIGIT is an immune checkpoint inhibitor, which interacts with CD155 expressed on antigen-presenting cells or tumor cells to down-regulate T cell and Natural Killer (NK) cell functions. EOS-448 is a novel fully human IgG1 mAb against the TIGIT receptor to treat a wide range of tumor types expressing ligands of TIGIT and/or being infiltrated by TIGIT expressing immune cells. EOS-448 was designed to encompass multiple mechanisms to activate anti-tumor immunity, not only by restoring T cell effector functions, but also by depleting immunosuppressive Tregs or inducing direct cytotoxicity of TIGIT-expressing tumor cells and creating local inflammation by engaging Fcγ receptors on effector cells. During preclinical development, EOS-448 demonstrated potent competition with TIGIT-ligand binding as well as in vitro and ex-vivo ability to restore T cell function in human samples. EOS-448 has also confirmed preferred direct cytotoxicity on regulatory T cells when tested in human cancer samples and demonstrated a clean toxicity profile. EOS-448 has also demonstrated potent anti-tumor efficacy in a humanized mouse tumor model. For further information, please contact: Michel Detheux, CEO iTeos Therapeutics SA info@iteostherapeutics.com   Amber Fennell, Paul Kidwell, Matthew Neal and Sukaina Virji Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com   Sarah McCabe and Zofia Mita Stern Investor Relations, Inc. + 1 212 362 1200 iTeos@sternir.com  

  • iTeos Therapeutics to Present at Cowen 40th Annual Health Care Conference
    Corporate

    iTeos Therapeutics to Present at Cowen 40th Annual Health Care Conference

    Cambridge, MA  and Gosselies, Belgium – February 24, 2020 – iTeos Therapeutics SA, a privately-held biotechnology company developing innovative cancer immunotherapies, today announced that Michel Detheux, Ph.D., president and chief executive officer, will present at the upcoming Cowen 40th Annual Health Care Conference on Monday, March 2, 2020 at 3:30 p.m. ET in Boston, MA   For further information, please contact: Michel Detheux, CEO iTeos Therapeutics info@iteostherapeutics.com    Amber Fennell, Catherine Day, Matthew Neal and Sukaina Virji  Consilium Strategic Communications +44 203 709 5700 iteos@consilium-comms.com    Sarah McCabe Stern Investor Relations, Inc. +1 212 362 1200 sarah.mccabe@sternir.com